The National Institutes of Health took 16 months to issue a decision denying a request for the government to grant march-in rights to patents on Astellas Pharma, Inc.’s and Pfizer Inc.’s Xtandi (enzalutamide) without addressing the cost of the prostate cancer drug in the US.
The agency’s rationale for refusing the petition shows once again that NIH does not want to consider drug pricing as a factor for invoking march-in rights to